Penile Cancer

P2, N=28, Recruiting, Mayo Clinic | Trial completion date: Nov 2026 --> Jun 2028 | Trial primary completion date: Nov 2026 --> Jun 2028

In summary, based on multi-omics analysis, this study establishes a systemic mechanism that links tumor lipid metabolism, immune suppression, and therapeutic response in CCA. Targeting the USP1-mediated metabolic-immune axis not only significantly suppresses tumor progression but also enhances the efficacy of immunotherapy. These findings construct a conceptual framework that integrates metabolic reprogramming, immune evasion, and treatment sensitivity, thereby establishing USP1 as a precision therapeutic target with broad biological and clinical importance for patients with CCA.

Our study systematically addressed the effects of aging on PSCC and identified IL1B as a potential prognostic marker for PSCC, offering a framework for the classification management and treatment of PSCC patients.

P2, N=798, Active, not recruiting, National Cancer Institute (NCI) | Trial primary completion date: May 2027 --> May 2026

A partial penectomy and adjuvant chemotherapy with vincristine, doxorubicin, and cyclophosphamide alternating once every 2 weeks with ifosphamide and etoposide were performed, with no recurrence at one year. This case highlights the importance of initial management of tumors of undetermined type, where complete surgical treatment is key to improving disease-free survival (DFS). To our knowledge, this is the first reported case in France.

[18F]F-FAPI PET/CT demonstrates promising diagnostic performance in detecting ILN metastases in patients with PSCC compared to [18F]F-FDG. This modality holds potential value in refining patient selection for inguinal lymph node dissection and reducing unnecessary surgical morbidity.

Based on these results, TAM administration in healthy rats was associated with increased penile oxidative stress, while O3FA attenuated some of these changes.

In most HPV-positive metastatic cases, the same HPV genotypes were detected in both the metastasis and the penile tumor. Both p16 staining and histological subtype can serve as surrogates for molecular HPV testing in lower resourced settings. In this dataset, no significant association was found between HPV status, p16 expression, or p53 expression and the presence of ILNM, suggesting their limited utility as predictive markers for ILNM in penile cancer.

P2, N=818, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027

P2, N=47, Recruiting, Sun Yat-sen University | Not yet recruiting --> Recruiting

These results demonstrate the strong immunostimulatory capacity of CC-3 and validate B7-H3 as a relevant target for T cell-based immunotherapy in PeCa. Our findings support the ongoing inclusion of PeCa patients in the clinical CC-3 trial and encourage further development of B7-H3-directed strategies for this rare, understudied malignancy.

P=N/A, N=72, Active, not recruiting, University College Cork | Trial primary completion date: Mar 2026 --> Jun 2026